Pathway-based Screening Strategy for Multitarget Inhibitors of Diverse Proteins in Metabolic Pathways

PLoS Computational Biology

Volumn 9, Issue 7, 2013, Pages

  Hsu, Kai Cheng ^a   Cheng, Wen Chi ^b   Chen, Yen Fu ^c   Wang, Wen Ching ^b   Yang, Jinn Moon ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGICAL SYSTEMS; DIAGNOSIS; DRUG THERAPY; PROTEINS;

BINDING MECHANISMS; BIOLOGICAL FUNCTIONS; DIVERSE PROTEINS; HIT RATE; METABOLIC PATHWAYS; MULTI-TARGETS; SCREENING STRATEGY; SHIKIMATES; TARGET PROTEINS; VIRTUAL SCREENING;

ANCHORS;

BACTERIAL ENZYME; HTS 02873; NSC 45174; NSC 45611; OXIDOREDUCTASE; PHOSPHOTRANSFERASE; PROTEIN; PROTEIN INHIBITOR; RH 00037; SHIKIMATE DEHYDROGENASE; SHIKIMATE KINASE; SHIKIMIC ACID; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HELICOBACTER PYLORI; IC 50; METABOLISM; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; STRUCTURAL HOMOLOGY;

HELICOBACTER PYLORI;

EID: 84880848738     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003127     Document Type: Article

References (39)

1. Bleicher KH, Bohm HJ, Muller K, Alanine AI, (2003) Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Discov 2: 369-378.
2. Lyne PD, (2002) Structure-based virtual screening: an overview. Drug Discov Today 7: 1047-1055.
3. Kitchen DB, Decornez H, Furr JR, Bajorath J, (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery 3: 935-949.
4. Shoichet BK, McGovern SL, Wei B, Irwin J, (2002) Lead discovery using molecular docking. Current Opinion in Chemical Biology 6: 439-446.
5. Ghosh S, Nie AH, An J, Huang ZW, (2006) Structure-based virtual screening of chemical libraries for drug discovery Current Opinion in Chemical. Biology 10: 194-202.
6. Moscona A, (2005) Oseltamivir resistance- disabling our influenza defenses. N Engl J Med 353: 2633-2636.
7. Chen LM, Perlina A, Lee CJ, (2004) Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. Journal of Virology 78: 3722-3732.
8. Dey A, Tergaonkar V, Lane DP, (2008) Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappa B pathways. Nat Rev Drug Discov 7: 1031-1040.
9. Knight ZA, Lin H, Shokat KM, (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130-137.
10. Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R, (2008) Novel paradigms for drug discovery: computational multitarget screening. Trends Pharmacol Sci 29: 62-71.
11. Zhang Y, Thiele I, Weekes D, Li ZW, Jaroszewski L, et al. (2009) Three-dimensional structural view of the central metabolic network of Thermotoga maritima. Science 325: 1544-1549.
12. Jensen RA, (1976) Enzyme recruitment in evolution of new function. Annu Rev Microbiol 30: 409-425.
13. Chen YF, Hsu KC, Lin SR, Wang WC, Huang YC, et al. (2010) SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties. Nucleic Acids Res 38: W424-W430.
14. Hsu KC, Cheng WC, Chen YF, Wang HJ, Li LT, et al. (2012) Core site-moiety maps reveal inhibitors and binding mechanisms of orthologous proteins by screening compound libraries. PLoS One 7: e32142.
15. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, et al. (1997) The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388: 539-547.
16. Alm RA, Ling LSL, Moir DT, King BL, Brown ED, et al. (1999) Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397: 176-180.
17. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, et al. (1998) Evidence for the shikimate pathway in apicomplexan parasites. Nature 393: 801-805.
18. Han C, Wang L, Yu K, Chen L, Hu L, et al. (2006) Biochemical characterization and inhibitor discovery of shikimate dehydrogenase from Helicobacter pylori. FEBS J 273: 4682-4692.
19. Cheng WC, Chang YN, Wang WC, (2005) Structural basis for shikimate-binding specificity of Helicobacter pylori shikimate kinase. J Bacteriol 187: 8156-8163.
20. Yang JM, Chen CC, (2004) GEMDOCK: a generic evolutionary method for molecular docking. Proteins: Structure, Function, and Bioinformatics 55: 288-304.
21. Ewing TJ, Makino S, Skillman AG, Kuntz ID, (2001) DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 15: 411-428.
22. Kramer B, Rarey M, Lengauer T, (1999) Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37: 228-241.
23. Jones G, Willett P, Glen RC, Leach AR, Taylor R, (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748.
24. Yang JM, Shen TW, (2005) A pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators. Proteins-Structure Function and Bioinformatics 59: 205-220.
25. Yang JM, Chen YF, Tu YY, Yen KR, Yang YL, (2007) Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors. PLoS One 2: e428.
26. Chin KH, Lee YC, Tu ZL, Chen CH, Tseng YH, et al. (2010) The cAMP receptor-like protein CLP is a novel c-di-GMP receptor linking cell-cell signaling to virulence gene expression in Xanthomonas campestris. J Mol Biol 396: 646-662.
27. Yang MC, Guan HH, Yang JM, Ko CN, Liu MY, et al. (2008) Rational design for crystallization of beta-lactoglobulin and vitamin D-3 complex: revealing a secondary binding site. Cryst Growth Des 8: 4268-4276.
28. Bagautdinov B, Kunishima N, (2007) Crystal structures of shikimate dehydrogenase AroE from Thermus thermophilus HB8 and its cofactor and substrate complexes: Insights into the enzymatic mechanism. J Mol Biol 373: 424-438.
29. Hartmann MD, Bourenkov GP, Oberschall A, Strizhov N, Bartunik HD, (2006) Mechanism of phosphoryl transfer catalyzed by shikimate kinase from Mycobacterium tuberculosis. J Mol Biol 364: 411-423.
30. Lindner HA, Nadeau G, Matte A, Michel G, Menard R, et al. (2005) Site-directed mutagenesis of the active site region in the quinate/shikimate 5-dehydrogenase YdiB of Escherichia coli. J Biol Chem 280: 7162-7169.
31. Cheng WC, Chen YF, Wang HJ, Hsu KC, Lin SC, et al. (2012) Structures of Helicobacter pylori shikimate kinase reveal a selective inhibitor-induced-fit mechanism. PLoS One7: e33481.
32. Landau M, Mayrose I, Rosenberg Y, Glaser F, Martz E, et al. (2005) ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. Nucleic Acids Res 33: W299-302.
33. Duesberg P, Stindl R, Hehlmann R, (2000) Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A 97: 14295-14300.
34. Palese P, Young JF, (1982) Variation of Influenza-A, Influenza-B, and Influenza-C viruses. Science 215: 1468-1474.
35. Ding CH, (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs 7: 1020-1025.
36. Chen CC, Hwang JK, Yang JM, (2006) (PS)(2): protein structure prediction server. Nucleic Acids Research 34: W152-W157.
37. Carpenter EP, Hawkins AR, Frost JW, Brown KA, (1998) Structure of dehydroquinate synthase reveals an active site capable of multistep catalysis. Nature 394: 299-302.
38. Shindyalov IN, Bourne PE, (1998) Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng 11: 739-747.
39. Gan JH, Gu YJ, Li Y, Yan HG, Ji XH, (2006) Crystal structure of Mycobacterium tuberculosis shikimate kinase in complex with shikimic acid and an ATP analogue. Biochemistry 45: 8539-8545.